CHIRON CORPORATION
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1981-01-01
- Employees
- 5.4K
- Market Cap
- -
- Website
- http://www.chiron.com/
Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine
- Conditions
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2005-12-06
- Lead Sponsor
- Chiron Corporation
- Target Recruit Count
- 264
- Registration Number
- NCT00262015
- Locations
- ๐ฌ๐ง
University of Oxford, The Oxford Vaccine Group, Oxford, United Kingdom
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
- Conditions
- First Posted Date
- 2005-01-07
- Last Posted Date
- 2006-02-06
- Lead Sponsor
- Chiron Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT00100737
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer
- Conditions
- First Posted Date
- 2003-02-13
- Last Posted Date
- 2006-07-11
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00054873
- Locations
- ๐บ๐ธ
Tower Hematology Oncology Medical Group, Los Angeles, California, United States
๐บ๐ธWashington University School of Medicine, St. Louis, Missouri, United States
๐บ๐ธThe University of Chicago, Chicago, Illinois, United States
Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2003-01-16
- Last Posted Date
- 2006-07-11
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00051688
- Locations
- ๐บ๐ธ
Cancer Institute Medical Group, Santa Monica, California, United States
๐บ๐ธACRC/Arizona Clinical Research Center, Tucson, Arizona, United States
๐บ๐ธUSC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
- Conditions
- First Posted Date
- 2002-09-16
- Last Posted Date
- 2006-02-06
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00045864
- Locations
- ๐บ๐ธ
Hematology /Oncology Consultants Inc., Columbus, Ohio, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธThe Cleveland Clinic Foundation, Cleveland, Ohio, United States
Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
- Conditions
- First Posted Date
- 2002-09-16
- Last Posted Date
- 2006-02-06
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00045877
- Locations
- ๐บ๐ธ
Fletcher Allen Health Care, Burlington, Vermont, United States
๐บ๐ธSanta Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States
๐บ๐ธLouisiana State University Health Sciences Center and VA, Shreveport, Louisiana, United States
A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Chiron Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00002204
- Locations
- ๐บ๐ธ
Creighton Univ Med Ctr / Ped Infect Disease Div, Omaha, Nebraska, United States
Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Chiron Corporation
- Target Recruit Count
- 212
- Registration Number
- NCT00002449
- Locations
- ๐บ๐ธ
Anderson Clinical Research, Pittsburgh, Pennsylvania, United States
๐บ๐ธAIDS Research Alliance - Chicago, Chicago, Illinois, United States
๐บ๐ธNorthstar Med Clinic, Chicago, Illinois, United States
A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00002321
- Locations
- ๐บ๐ธ
Med College of Ohio, Toledo, Ohio, United States
A Phase I Study of Subcutaneously Administered Proleukin (Aldesleukin) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Chiron Corporation
- Registration Number
- NCT00002107
- Locations
- ๐บ๐ธ
Davies Med Ctr / c/o HIV Institute, San Francisco, California, United States